Investigating the role of EZH2 in ribosomal RNA methylation and its impact on prostate cancer.
A non-canonical role for EZH2 in rRNA methtlation
This study is looking at how a protein called EZH2 affects the way our cells make proteins, which is important for understanding how prostate cancer might grow, and it could help find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10872308 on NIH RePORTER |
What this research studies
This research explores how the EZH2 protein, known for its role in modifying histones, also influences ribosomal RNA (rRNA) methylation, which is crucial for protein synthesis. By examining the interaction between EZH2 and Fibrillarin (FBL), the study aims to understand how changes in rRNA methylation can affect cancer progression, particularly in prostate cancer. The researchers will utilize various molecular biology techniques to assess the effects of EZH2 on ribosomal functions and cancer outcomes, providing insights into potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with prostate cancer, particularly those exhibiting high levels of EZH2 and FBL.
Not a fit: Patients with non-cancerous conditions or those without prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating prostate cancer by targeting the epigenetic mechanisms involved in tumor progression.
How similar studies have performed: While the role of EZH2 in histone modification is well-established, the specific investigation of its non-canonical role in rRNA methylation is relatively novel and has not been extensively studied.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.